Ito Mikiko, Kimura Hiroyuki, Yoshida Keizo, Kimura Yuki, Ozaki Norio, Kurita Kenichi
Department of Oral and Maxillofacial Surgery, School of Dentistry, Aichi Gakuin University, Nagoya, Aichi, Japan.
Clin Neuropharmacol. 2010 Mar-Apr;33(2):79-83. doi: 10.1097/WNF.0b013e3181cb5793.
The effect of milnacipran for the treatment of chronic pain in the orofacial region, including burning mouth syndrome (BMS) and atypical odontalgia (AO), was assessed while accounting for the influence of concurrent depressive symptoms on the pain-relieving effect.
Milnacipran was administered for 12 weeks to 36 patients with chronic pain in the orofacial region (3 men and 29 women, aged between 22 and 76 years with a mean age of 59 years). Of those patients, 22 and 10 patients had BMS and AO, respectively. The initial dose of milnacipran was 15 mg a day, and the dose was raised up to 100 mg a day. Pain was assessed using the visual analog scale, and symptoms of depression were evaluated using the Hamilton Depression Rating Scale at baseline and at weeks 1, 2, 4, 6, 8, 10, and 12 of the study treatment.
Data from 32 patients who completed the study were included in the analysis. The visual analog scale score significantly decreased after the 12-week treatment, and it showed a similar time course of decline irrespective of concurrent depressive symptoms during the 12 weeks.
Treatment with milnacipran resulted in a significant improvement of chronic pain in the orofacial region irrespective of concurrent symptoms of depression. The present results suggested that milnacipran may be an effective agent for treatment of such disorders.
评估米那普明治疗口面部慢性疼痛（包括灼口综合征（BMS）和非典型牙痛（AO））的效果，同时考虑并发抑郁症状对止痛效果的影响。
对36例口面部慢性疼痛患者（3例男性和29例女性，年龄在22至76岁之间，平均年龄59岁）给予米那普明治疗12周。其中，分别有22例和10例患者患有BMS和AO。米那普明的初始剂量为每日15毫克，剂量可增至每日100毫克。在基线以及研究治疗的第1、2、4、6、8、10和12周，使用视觉模拟量表评估疼痛，并使用汉密尔顿抑郁量表评估抑郁症状。
分析纳入了32例完成研究的患者的数据。12周治疗后视觉模拟量表评分显著降低，且在12周内，无论是否并发抑郁症状，其下降的时间进程相似。
无论是否并发抑郁症状，米那普明治疗均可显著改善口面部慢性疼痛。目前的结果表明，米那普明可能是治疗此类疾病的有效药物。
